Table 2.
Baseline characteristics of the participants.
| Study ID | Number of participants in each group |
Age (years), mean (SD) |
Gender (male), N. (%) |
Dry weight (kg), mean (SD) |
Time since diagnosis of ESKD (years), mean (SD) |
Time since initiation of dialysis (years), mean (SD) |
Duration of pruritus (years), mean (SD) |
Cause of chronic kidney disease no. (%) |
Baseline use of anti-pruritic medication, N. (%) |
Baseline scores, mean (SD) |
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diabetes |
Hypertension |
Glomerulonephritis |
Cystic disease |
Other |
WI-NRs score |
5-D itch scale total score |
Skindex-10 scale total score |
|||||||||||||||||||||||||
| DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | DFK | Placebo | |
| Fishbane et al. [8] | 189 | 188 | 58.2 (11.2) | 56.8 (13.9) | 112 (59.3) | 118 (62.8) | 85.9 (20.3) | 85.0 (21.1) | 4.7 (3.9) | 5.7 (5.2) | 4.4 (4) | 4.7 (4.2) | 3.2 (3.2) | 3.5 (3.4) | 108 (57.1) | 95 (50.5) | 59 (31.2) | 73 (38.8) | 9 (4.8) | 7 (3.7) | 3 (1.6) | 3 (1.6) | 10 (5.3) | 10 (5.3) | 72 (38.1) | 78 (41.5) | 7.1 (1.4) | 7.3 (1.6) | 16.9 (3.5) | 17.9 (3.5) | 36.2 (14.4) | 38.3 (15.4) |
| Fishbane et al. [7] | 44 | 45 | 57 (12.75) | 60 (14.25) | 26 (59.1) | 28 (62.2) | 83.5 (20.9) | 81.0 (19.8) | 5.9 (4.9) | 6.6 (5.4) | 5.4 (4.9) | 5.9 (4.9) | 4.7 (3.9) | 4.4 (4.7) | 24 (54.5) | 21 (46.7) | 21 (47.7) | 21 (46.7) | 6 (13.6) | 5 (11.1) | 2 (4.5) | 0 | 2 (4.5) | 1 (2.2) | 20 (45.5) | 18 (40.0) | 7.1 (1.4) | 6.8 (1.5) | 17.3 (3.6) | 17.2 (3.1) | 35.1 (13.4) | 35.5 (12.4) |
| Narita et al. [14] | 61 | 63 | 65.6 (11.4) | 64.1 (12.7) | 45 (74) | 43 (68) | 59.98 (11.22) | 60.63 (12.71) | NA | NA | 6.7 (7.2) | 6.8 (6.1) | 4.5 (4.4) | 4.3 (4.4) | 32 (52.5) | 27 (42.9) | NA | NA | 11 (18) | 10 (15.9) | 0 | 3 (4.8) | 4 (6.6) | 8 (12.7) | NA | NA | 6.83 (1.4) | 6.53 (1.31) | NA | NA | NA | NA |
| Narita et al. [13] | 85 | 88 | 64.4 (10.5) | 64.1 (12.7) | 74 (87) | 72 (82) | 62.64 (11.63) | 63.33 (12.94) | NA | NA | 8.4 (7.6) | 7.9 (6.7) | 5.7 (5.5) | 4.6 (3.8) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 6.57 (1.29) | 6.40 (1.28) | 15.7 (2.8) | 15.4 (3.0) | NA | NA |
| Yosipovitch et al. [12] | 66 | 67 | 69.0 (12.0) | 65.6 (12.1) | 33 (50.0) | 37 (55.2) | 84.0 (18.3) | 87.8 (18.7) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 24 (36.4) | 28 (41.8) | 7.0 (1.2) | 7.0 (1.1) | 16.2 (3.1) | 16.8 (3.1) | 33.1 (14.3) | 34.9 (14.0) |
Note: NA: not available; SD: standard deviation; ESKD: end stage kidney disease; WI-NRS: Worst Itch Intensity Numerical Rating Scale.